All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1500+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Merck & Co.'s clesrovimab (anti-RSV F), targeting RSV infections in newbornws, expects FDA approval decision by June 2025
Monoclonal antibody, respiratory syncytial virus - Read more

THE GOOD
Business Development

Portage Biotech to sell subsidiary iOx Therapeutics, including lead clinical asset PORT-2 (iNKT engager), to Immunova
Small molecule, melanoma, lung cancer - Read more

THE GOOD
Clinical Trials

Actuate Therapeutics' elraglusib (GSK-3 beta inhibitor), improves survival in metastatic pancreatic ductal adenocarcinoma Ph1/2 trial in combo with gemcitabine/nab-paclitaxel
Small molecule, pancreatic cancer - Read more

Regeneron and Bayer's high-dose Eylea (vascular endothelial growth factor inhibitor) met Ph3 endpoint in macular edema following retinal vein occlusion, planning global filings
Fusion protein, macular edema following retinal vein occlusion - Read more

Teva Pharmaceuticals and Sanofi's duvakitug (targeting tumor necrosis factor-like ligand 1A) shows positive Ph2b results in ulcerative colitis and Crohn’s disease
Monoclonal antibody, ulcerative colitis, Crohn’s disease - Read more

Biomea Fusion's icovamenib (menin inhibitor) shows positive Ph2 results in Type 2 diabetes, improving HbA1c levels across multiple dosing regimens
Small molecule, type 2 diabetes - Read more

Affimed's AFM24 (targeting EGFR) combined with atezolizumab, shows positive Ph1/2a results in advanced non-small cell lung cancer
Bispecific antibody, lung cancer - Read more

Tenaya Therapeutics's TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy delivers promising early Ph1 data
Gene therapy, hypertrophic cardiomyopathy - Read more

PRESENTED BY YOU?
Get the attention of 1500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Earnings & Finances

Pfizer’s aiming for a more upbeat 2025 - forecasts 2025 of $61B-$64B, matching 2024 expectations, with a potential 5% increase in 2025
Big pharma, earnings guidance - Read more

THE GOOD
Fundraises

Precision Neuroscience $102M Series C, advancing AI-powered brain implants and clinical research for brain-computer interface development.
Medical device, brain-computer interface - Read more

Akamis Bio $60M Series A, advancing NG-350A in Phase 1b trial for locally advanced rectal cancer using its T-SIGn platform.
Oncolytic gene therapy, rectal cancer - Read more

Indapta Therapeutics $22.5M funding, accelerating clinical development of allogeneic NK cell therapy for blood cancers and autoimmune diseases.
Cell therapy, liquid cancer, autoimmune, allogeneic NK cell - Read more

NeuroKaire $10M funding, treatment-optimizing personalized medicine solutions in psychiatric and neurological diseases
Personalized medicine, treatment selection - Read more

Reviva Pharmaceuticals $18M public offering, advancing R&D and corporate initiatives for CNS, inflammatory, and cardiometabolic disease therapies.
Small molecule, central nervous system, inflammation, cardiometabolic - Read more

CG Oncology closes $238M public offering, developing bladder cancer therapies
Oncolytic immunotherapy, bladder cancer - Read more

Candel Therapeutics closes $92M public offering, advancing cancer therapies, including pre-funded warrants for additional shares.
Viral immunotherapy, prostate cancer - Read more

THE GOOD
Investments

Roswell Park GMP Engineering and Cell Manufacturing Facility opens as New York's first cell and gene therapy hub, a $98M GMP facility to boost R&D and create new jobs
Cell therapy, gene therapy, manufacturing, research & development - Read more

THE GOOD
Lawsuits

Sandoz settles price-fixing litigation for $275M, resolving claims from 2009-2019 without admitting wrongdoing
Generic, drug pricing, price-fixing - Read more

THE GOOD
Mergers & Acquisitions

Merck KGaA's Life Science business to acquire HUB Organoids
Organoids, drug development, non-animal testing - Read more

Ultimovacs and Zelluna Immunotherapy announced merger, combining expertise in cancer immunotherapy
Cell therapy, solid tumor, cancer vaccine, allogeneic TCR-NK cell therapy - Read more

THE GOOD
Partnerships

Terray Therapeutics, Gilead Sciences AI-powered drug discovery partnership
Small molecule, drug discovery, AI - Read more

Scailyte, Visterra research collaboration to develop treatments for autoimmune diseases using AI-powered biomarker discovery and biologics expertise.
Antibody, autoimmune, AI, biomarkers - Read more

Silexion Therapeutics, Evonik ongoing collaboration to develop advanced siRNA formulation for KRAS-driven cancers using Evonik’s PLGA microparticles
siRNA, cancer, microparticles, drug delivery - Read more

Orexo, Abera Bioscience collaboration to develop mucosal vaccines using Orexo’s AmorphOX drug delivery technology and Abera's vaccine platform
Vaccine, mucosal vaccine, nasal vaccine, drug delivery - Read more

SK Biopharmaceuticals, ProEn Therapeutics research collab to advance preclinical radiopharmaceutical candidates and expand oncology pipeline by 2027
Radiopharm, cancer, drug development - Read more

THE GOOD
Politics & Policy

Pfizer CEO Albert Bourla has developed a “good relation” with incoming HHS head RFK Jr., as potential immunization policy changes loom with incoming Trump administration
Big pharma, vaccine, immunization policy - Read more

THE GOOD
Research

Researchers at Université de Montréal show that endocannabinoids in the brain, particularly in the nucleus accumbens, regulate body weight; mice studies
Small molecule, obesity, brain - Read more

A gene-edited pig kidney was transplanted into a third patient, marking xenotransplantation’s progress towards clinical trials
Gene-edited organs, xenotransplantation - Read more [Paywall]

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Merck & Co. discontinues vibostolimab (targeting TIGIT) and favezelimab (targeting LAG3) development after Ph3 failure in combination with Keytruda for non-small cell lung cancer
Monoclonal antibody, lung cancer - Read more

UCB's Novartis-partnered minzasolmin (targeting alpha-synuclein) flops in Parkinson's disease Ph2a trial
Small molecule, Parkinson’s disease - Read more

THE BAD
Politics & Policy

Pharmacy benefit managers fight back against PBM reform (and new transparency rules) included in US government’s “larger-than-anticipated“ end-of-year healthcare package
Pharmacy benefit manager, drug pricing - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here